Ongoing developments in sporadic inclusion body myositis.
Sporadic inclusion body myositis (IBM) is an acquired muscle disorder associated with ageing, for which there is no effective treatment. Ongoing developments include: genetic studies that may provide insights regarding the pathogenesis of IBM, improved histopathological markers, the description of a new IBM autoantibody, scrutiny of the diagnostic utility of clinical features and biomarkers, the refinement of diagnostic criteria, the emerging use of MRI as a diagnostic and monitoring tool, and new pathogenic insights that have led to novel therapeutic approaches being trialled for IBM, including treatments with the objective of restoring protein homeostasis and myostatin blockers. The effect of exercise in IBM continues to be investigated. However, despite these ongoing developments, the aetiopathogenesis of IBM remains uncertain. A translational and multidisciplinary collaborative approach is critical to improve the diagnosis, treatment, and care of patients with IBM.
MRC Centre for Neuromuscular Diseases, Institute of Neurology, University College London, Box 102, 8-11 Queen Square, London, WC1N 3BG, UK, p.machado@ucl.ac.uk.
Pedro M
PM
Machado
Mhoriam
M
Ahmed
Stefen
S
Brady
Qiang
Q
Gang
Estelle
E
Healy
Jasper M
JM
Morrow
Amanda C
AC
Wallace
Liz
L
Dewar
Gita
G
Ramdharry
Matthew
M
Parton
Janice L
JL
Holton
Henry
H
Houlden
Linda
L
Greensmith
Michael G
MG
Hanna
D000375:Aging; D015415:Biomarkers; D006801:Humans; D018482:Muscle, Skeletal / Q000473:pathology*; D018979:Myositis, Inclusion Body / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology
D015415:Biomarkers